

Non-Oncology Biopharmaceuticals Market - 2024-2033

<https://marketpublishers.com/r/NA9510CD9705EN.html>

Date: May 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: NA9510CD9705EN

Abstracts

The Non-Oncology Biopharmaceuticals Market was valued at US\$ 194.39 Billion in 2024 and is anticipated to reach US\$ 313.70 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non-Oncology Biopharmaceuticals Market.

This report delivers a comprehensive overview of the Non-Oncology Biopharmaceuticals Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Oncology Biopharmaceuticals Market. The Non-Oncology Biopharmaceuticals Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Non-Oncology Biopharmaceuticals Market Scope:

Key Players

Novartis AG

Eli Lilly and Company

GlaxoSmithKline

Amgen Inc

AbbVie Inc

AstraZeneca

Novo Nordisk A/S

Takeda Pharmaceutical Company Ltd

Elusys Therapeutics

Swedish Orphan Biovitrum

Major Highlights

This report delivers a comprehensive overview of the Non-Oncology Biopharmaceuticals Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non-Oncology Biopharmaceuticals Market. The Non-Oncology Biopharmaceuticals Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest

of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the

privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

3. MARKET HIGHLIGHTS AND STRATEGIC TAKEAWAYS

- 3.1. Key Trends and Future Projections

4. SNIPPET BY PRODUCT TYPE

- 4.1. Snippet by Application
- 4.2. Snippet by Route of Administration
- 4.3. Snippet by Distribution Channel
- 4.4. Snippet by Region

5. DYNAMICS

5.1. Impacting Factors

5.1.1. Drivers

- 5.1.1.1. Increasing Prevalence of Chronic Diseases

- 5.1.1.2. Advancements in Biologics and Targeted Therapies

- 5.1.1.3. XX

5.2. Restraints

5.2.1. Stringent Regulatory Requirements

- 5.2.1.1. Limited Access in Low- and Middle-Income Countries

- 5.2.1.2. XX

5.2.2. Opportunity

- 5.2.2.1. Growth in Homecare and Self-Administration of Biologics

- 5.2.2.2. XX

5.2.3. Impact Analysis

6. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 6.1. Market Leaders and Pioneers
 - 6.1.1. Emerging Pioneers and Prominent Players
 - 6.1.2. Established leaders with largest largest-selling Brand
 - 6.1.3. Market leaders with established products & Services
- 6.2. CXO Perspectives
- 6.3. Latest Developments and Breakthroughs
- 6.4. Case Studies/Ongoing Research
- 6.5. Regulatory and Reimbursement Landscape
 - 6.5.1. North America
 - 6.5.2. Europe
 - 6.5.3. Asia Pacific
 - 6.5.4. South America
 - 6.5.5. Middle East & Africa
- 6.6. Porter's Five Force Analysis
- 6.7. Supply Chain Analysis
- 6.8. Patent Analysis
- 6.9. SWOT Analysis
- 6.10. Unmet Needs and Gaps
- 6.11. Recommended Strategies for Market Entry and Expansion
- 6.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 6.13. Pricing Analysis and Price Dynamics
- 6.14. Key Opinion Leaders

7. GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS MARKET, BY PRODUCT TYPE

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
 - 7.1.2. Market Attractiveness Index, By Product Type
- 7.2. Monoclonal Antibodies (mAbs)*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Vaccines
- 7.4. Recombinant Proteins
- 7.5. Hormones
- 7.6. Interferons
- 7.7. Others

8. GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS MARKET, BY

APPLICATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

8.1.2. Market Attractiveness Index, By Application

8.2. Autoimmune Diseases*

8.2.1. Introduction

8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?

8.3. Infectious Diseases

8.4. Respiratory Disorders

8.5. Cardiovascular Diseases

8.6. Others

9. GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION

9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

9.1.2. Market Attractiveness Index, By Route of Administration

9.2. Injectable*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?

9.3. Oral

9.4. Topical

9.5. Nasal

9.6. Others

10. GLOBAL NON-ONCOLOGY BIOPHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL

10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10.1.2. Market Attractiveness Index, By Distribution Channel

10.2. Hospital Pharmacies*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)?

10.3. Retail Pharmacies

10.4. Online Pharmacies

11. NON-ONCOLOGY BIOPHARMACEUTICALS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.1.1. Market Attractiveness Index, By Region

11.1.2. North America

11.1.2.1. Introduction

11.1.2.2. Key Region-Specific Dynamics

11.1.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

11.1.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.1.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.1.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution

Channel

11.1.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.1.2.7.1. U.S.

11.1.2.7.2. Canada

11.1.2.7.3. Mexico

11.1.3. Europe

11.1.3.1. Introduction

11.1.3.2. Key Region-Specific Dynamics

11.1.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

11.1.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.1.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

11.1.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution

Channel

11.1.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.1.3.7.1. Germany

11.1.3.7.2. U.K.

11.1.3.7.3. France

11.1.3.7.4. Spain

11.1.3.7.5. Italy

11.1.3.7.6. Rest of Europe

11.1.4. South America

11.1.4.1. Introduction

11.1.4.2. Key Region-Specific Dynamics

11.1.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

11.1.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.1.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.1.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.1.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.1.4.7.1. Brazil

11.1.4.7.2. Argentina

11.1.4.7.3. Rest of South America

11.1.5. Asia-Pacific

11.1.5.1. Introduction

11.1.5.2. Key Region-Specific Dynamics

11.1.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

11.1.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.1.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.1.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11.1.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11.1.5.7.1. China

11.1.5.7.2. India

11.1.5.7.3. Japan

11.1.5.7.4. South Korea

11.1.5.7.5. Rest of Asia-Pacific

11.1.6. Middle East and Africa

11.1.6.1. Introduction

11.1.6.2. Key Region-Specific Dynamics

11.1.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

11.1.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11.1.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

11.1.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

12.1. Competitive Overview and Key Market Players

12.1.1. Market Share Analysis and Positioning Matrix

- 12.1.2. Strategic Partnerships, Mergers & Acquisitions
- 12.1.3. Key Developments in Product Type Portfolios and Innovations
- 12.1.4. Company Benchmarking

13. COMPANY PROFILES

- 13.1. Novartis AG*
 - 13.1.1. Company Overview
 - 13.1.2. Product Type Portfolio
 - 13.1.2.1. Product Type Description
 - 13.1.2.2. Product Type Key Performance Indicators (KPIs)
 - 13.1.2.3. Historic and Forecasted Product Type Sales
 - 13.1.2.4. Product Type Sales Volume
 - 13.1.3. Financial Overview
 - 13.1.3.1. Company Revenue
 - 13.1.3.1.1. Geographical Revenue Shares
 - 13.1.3.1.1.1. Revenue Forecasts
 - 13.1.3.1.2. Key Developments
 - 13.1.3.1.2.1. Mergers & Acquisitions
 - 13.1.3.1.2.2. Key Product Type Development Activities
 - 13.1.3.1.2.3. Regulatory Approvals, etc.
 - 13.1.3.1.3. SWOT Analysis
- 13.2. Eli Lilly and Company
- 13.3. GlaxoSmithKline
- 13.4. Amgen Inc
- 13.5. AbbVie Inc
- 13.6. AstraZeneca
- 13.7. Novo Nordisk A/S
- 13.8. Takeda Pharmaceutical Company Ltd
- 13.9. Elusys Therapeutics
- 13.10. Swedish Orphan Biovitrum (LIST NOT EXHAUSTIVE)

14. ASSUMPTIONS AND RESEARCH METHODOLOGY

- 14.1. Data Collection Methods
- 14.2. Data Triangulation
- 14.3. Forecasting Techniques
- 14.4. Data Verification and Validation

15. APPENDIX

15.1. About Us and Services

15.2. Contact Us

I would like to order

Product name: Non-Oncology Biopharmaceuticals Market - 2024-2033

Product link: <https://marketpublishers.com/r/NA9510CD9705EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NA9510CD9705EN.html>